BioXcel Therapeutics, Inc. (BTAI) Stock Score, Valuation & Financial Research
BioXcel Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 14/100.
Quick answer for BTAI
BioXcel Therapeutics, Inc. currently has a Wall Street Score of 14/100. The stored market price is $0.07. Its financial score is 4/100. Its valuation score is 0/100. The latest WSS change is +0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What BioXcel Therapeutics, Inc. does
BioXcel Therapeutics, Inc. is a biopharmaceutical firm that has reached the commercial phase, distinguishing itself by leveraging artificial intelligence to advance the creation of transformative therapies in the fields of neuroscience and immuno-oncology. Their distinctive methodology, termed 'drug re-innovation,' involves harnessing the power of big data and proprietary machine learning algorithms to uncover novel therapeutic applications for existing approved medications or drug candidates with established clinical validation. The company's flagship commercial offering, IGALMI (known during development as BXCL501), is a unique sublingual film delivering dexmedetomidine, designed for the rapid management of agitation experienced by adults with schizophrenia or bipolar I or II disorder. Beyond its current commercial use, BXCL501 is also undergoing further clinical investigation. Studies
BTAI financial snapshot
- Wall Street Score:
- 14/100
- Current price:
- $0.07
- Market capitalization:
- $2.3M
- Revenue:
- $742K
- Net income:
- $-70.9M
- Free cash flow:
- $-57.6M
- Cash:
- $12.8M
- Total debt:
- $104.5M
- EPS:
- -5.46
- Financial score:
- 4/100
- Valuation score:
- 0/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-57.6M, showing cash burn in the current stored period.
- The balance sheet shows $12.8M of cash versus $104.5M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.1 points: BTAI increased 0.1 points because overall fundamentals improved.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 4/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BTAI
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.